VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2021 | PARP inhibitors and AML: gemtuzumab plus talazoparib

Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, talks on the emerging role of PARP inhibitors in the treatment of acute myeloid leukemia (AML). Dr Wang reports that promising data has demonstrated the ability to enhance the effects of cytotoxic chemotherapy in pre-clinical models, specifically with antibody-drug conjugates such as gemtuzumab. Dr Wang also gives an overview of the rationale for these studies and discusses a Phase I trial (NCT04207190) of talazoparib in combination with gemtuzumab. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter